ZA200406917B - Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect - Google Patents

Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Info

Publication number
ZA200406917B
ZA200406917B ZA200406917A ZA200406917A ZA200406917B ZA 200406917 B ZA200406917 B ZA 200406917B ZA 200406917 A ZA200406917 A ZA 200406917A ZA 200406917 A ZA200406917 A ZA 200406917A ZA 200406917 B ZA200406917 B ZA 200406917B
Authority
ZA
South Africa
Prior art keywords
medicaments
produce
pulmonary administration
aerosol formulations
systemic effect
Prior art date
Application number
ZA200406917A
Other languages
English (en)
Inventor
Rebecca Jaine Davies
David Ganderton
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of ZA200406917B publication Critical patent/ZA200406917B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
ZA200406917A 2002-03-01 2004-08-31 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect ZA200406917B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects

Publications (1)

Publication Number Publication Date
ZA200406917B true ZA200406917B (en) 2006-06-28

Family

ID=27675679

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA200406918A ZA200406918B (en) 2002-03-01 2004-08-31 Pressurised metered dose inhalers containing solutions of beta-2 agonists
ZA200406917A ZA200406917B (en) 2002-03-01 2004-08-31 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
ZA200406919A ZA200406919B (en) 2002-03-01 2004-08-31 Formoterol superfine formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200406918A ZA200406918B (en) 2002-03-01 2004-08-31 Pressurised metered dose inhalers containing solutions of beta-2 agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200406919A ZA200406919B (en) 2002-03-01 2004-08-31 Formoterol superfine formulation

Country Status (27)

Country Link
US (1) US20050129621A1 (xx)
EP (2) EP1340492A1 (xx)
JP (1) JP2005519094A (xx)
KR (1) KR20040091050A (xx)
CN (2) CN1638731A (xx)
AR (2) AR038643A1 (xx)
AT (1) ATE488224T1 (xx)
AU (1) AU2003215597B2 (xx)
BR (1) BR0303348A (xx)
CA (1) CA2477879C (xx)
DE (1) DE60334973D1 (xx)
EA (1) EA008571B1 (xx)
ES (1) ES2358293T3 (xx)
GE (1) GEP20063985B (xx)
HR (1) HRP20040751A2 (xx)
IL (1) IL163842A0 (xx)
MA (1) MA27107A1 (xx)
MX (1) MXPA04008370A (xx)
NO (1) NO20034874L (xx)
NZ (1) NZ535019A (xx)
PE (1) PE20030949A1 (xx)
PL (1) PL372261A1 (xx)
TN (1) TNSN04148A1 (xx)
TW (1) TW200304833A (xx)
UA (2) UA81238C2 (xx)
WO (1) WO2003074023A1 (xx)
ZA (3) ZA200406918B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
CA2411047C (en) * 2000-05-22 2009-08-04 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
IL163843A0 (en) * 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
BRPI0414428A (pt) * 2003-09-15 2006-11-14 Vectura Ltd composições farmacêuticas
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
KR101297061B1 (ko) * 2004-07-02 2013-08-19 베링거 인겔하임 인터내셔날 게엠베하 추진제로서 tg 227 ea 또는 tg 134 a를함유하는 에어로졸 현탁액 제형
RU2457832C2 (ru) * 2005-09-25 2012-08-10 Сипла Лимитед Состав на основе тровентола
AU2006330943A1 (en) * 2005-12-21 2007-07-05 N30 Pharmaceuticals, Llc Stable S-nitrosothiol formulations
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
UY31235A1 (es) * 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
AU2011278693B2 (en) * 2010-07-12 2015-02-19 Xellia Pharmaceuticals Aps Treatment of lung infections by administration of Tobramycin by aerolisation
US20140023590A1 (en) 2010-09-22 2014-01-23 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof
AU2012267938B2 (en) 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2013096560A1 (en) * 2011-12-20 2013-06-27 Map Pharmaceuticals, Inc. Excipient-free aerosol formulation
GB201402513D0 (en) 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
WO2016187156A1 (en) * 2015-05-21 2016-11-24 Island Breeze Systems Ca, Llc Propellant based metered dose inhaler and food applicators and applicators
US11129848B2 (en) 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1011646T3 (da) * 1996-12-04 2005-09-19 Link Products Ltd Farmaceutiske præparater og indretninger til administration heraf
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
DE60031504T2 (de) * 1999-09-11 2007-04-05 Glaxo Group Ltd., Greenford Fluticasonpropionat arzneizubereitung
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
DK1280515T3 (da) * 2000-03-09 2007-06-11 Gw Pharma Ltd Farmaceutiske sammensætninger omfattende cannabis
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
CA2411047C (en) * 2000-05-22 2009-08-04 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
IL163843A0 (en) * 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
EP1480616A1 (en) 2004-12-01
NO20034874D0 (no) 2003-10-31
DE60334973D1 (de) 2010-12-30
CA2477879C (en) 2011-05-03
TW200304833A (en) 2003-10-16
ZA200406919B (en) 2006-06-28
PE20030949A1 (es) 2004-01-02
IL163842A0 (en) 2005-12-18
MXPA04008370A (es) 2004-11-26
AU2003215597A1 (en) 2003-09-16
MA27107A1 (fr) 2004-12-20
AR101593A2 (es) 2016-12-28
HRP20040751A2 (en) 2004-12-31
EA008571B1 (ru) 2007-06-29
GEP20063985B (en) 2006-12-11
US20050129621A1 (en) 2005-06-16
AU2003215597B2 (en) 2008-07-31
NZ535019A (en) 2006-09-29
PL372261A1 (en) 2005-07-11
UA80695C2 (en) 2007-10-25
NO20034874L (no) 2003-12-23
ATE488224T1 (de) 2010-12-15
CA2477879A1 (en) 2003-09-12
EP1340492A1 (en) 2003-09-03
KR20040091050A (ko) 2004-10-27
WO2003074023A1 (en) 2003-09-12
TNSN04148A1 (en) 2007-03-12
ES2358293T3 (es) 2011-05-09
JP2005519094A (ja) 2005-06-30
EP1480616B1 (en) 2010-11-17
EA200401006A1 (ru) 2005-04-28
BR0303348A (pt) 2004-07-13
CN101502500A (zh) 2009-08-12
CN1638731A (zh) 2005-07-13
ZA200406918B (en) 2006-06-28
AR038643A1 (es) 2005-01-19
UA81238C2 (en) 2007-12-25

Similar Documents

Publication Publication Date Title
ZA200406917B (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
EP1663159A4 (en) AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
HUS1800032I1 (hu) Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
SI2258394T1 (sl) Oralna farmacevtska oblika, ki vsebuje PDE 4 inhibitor kot aktivno sestavino in polivinilpirolidon kot ekscipient
EP1296723A4 (en) DRUG PREPARATION FOR AEROSOL
AU2753001A (en) A medicinal aerosol formulation
AU4519001A (en) A medicinal aerosol formulation
IL155088A0 (en) Medicinal aerosol formulations
SI1496876T1 (sl) Aerosolna formulacija za inhalacijo, ki vsebuje tiotropijev bromid
AU2623401A (en) A medicinal aerosol formulation
HK1102021A1 (en) Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative
EP1292283A4 (en) MEDICAL AEROSOL FORMULATION
GB0012522D0 (en) Improvements to pharmaceutical aerosol formulations
AU2001287930A1 (en) Pharmaceutical formulation for pulmonary or nasal administration
HRP20040757A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii
GB0024711D0 (en) Medicinal aerosol formulations
GB0128582D0 (en) Pharmaceutical aerosol formulations